Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study.

Dal Prato L, Borini A, Coticchio G, Cattoli M, Flamigni C

Human reproduction (Oxford, England)22 Jul 2004Cited by 24 (Europe PMC)

PMID15271868DOI10.1093/humrep/deh415PepBankPUB-15271868

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In ovarian stimulation patients, neither half-dose nor full-dose triptorelin produced a premature LH surge.
In plain wordsIn ovarian stimulation patients, neither half-dose nor full-dose triptorelin produced a premature LH surge.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changePremature LH surge
Study
n = 180
Comparator
Full-dose triptorelin 3.75 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.87 mg depot versus 3.75 mg depotAs given in this study (human).
Source sentences
Summary
There was no premature LH surge, with LH levels being lower in the full-dose group (1.04+/-0.05 versus 0.7+/-0.06 IU/l on the day of hCG).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 180 patients were randomized into two groups using sealed envelopes.
Summary · context
Pituitary desensitization was obtained in group 1 (90 patients) with half-dose (1.87 mg) triptorelin depot in the mid-luteal phase of their menstrual cycle, and in group 2 (90 patients) with full-dose (3.75 mg) triptorelin.
Report a problemFND-1527186801
02HumanRandomized controlled trialEfficacy outcome
In ovarian stimulation patients, LH on the hCG day was higher with half-dose than full-dose triptorelin.
In plain wordsIn ovarian stimulation patients, LH on the hCG day was higher with half-dose than full-dose triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseLH on hCG day
Study
n = 180
Comparator
Full-dose triptorelin 3.75 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.87 mg depot versus 3.75 mg depotAs given in this study (human).
Measurements
LH on day of hCG
1.04 IU/l
half-dose triptorelin, group 1 (SD 0.05)
LH on day of hCG
0.7 IU/l
full-dose triptorelin, group 2 (SD 0.06)
Source sentences
Summary
There was no premature LH surge, with LH levels being lower in the full-dose group (1.04+/-0.05 versus 0.7+/-0.06 IU/l on the day of hCG).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 180 patients were randomized into two groups using sealed envelopes.
Summary · context
Pituitary desensitization was obtained in group 1 (90 patients) with half-dose (1.87 mg) triptorelin depot in the mid-luteal phase of their menstrual cycle, and in group 2 (90 patients) with full-dose (3.75 mg) triptorelin.
Report a problemFND-1527186802
03HumanRandomized controlled trialEfficacy outcome
In ovarian stimulation patients, half-dose triptorelin required fewer FSH ampoules than full-dose triptorelin.
In plain wordsIn ovarian stimulation patients, half-dose triptorelin required fewer FSH ampoules than full-dose triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseFSH ampoules used
Study
n = 180
Comparator
Full-dose triptorelin 3.75 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.87 mg depot versus 3.75 mg depotAs given in this study (human).
Measurements
FSH ampoules used
42 ampoules
half-dose triptorelin, group 1 (SD 2)
FSH ampoules used
59 ampoules
full-dose triptorelin, group 2 (SD 3)
Source sentences
Summary
The number of FSH ampoules used was lower in group 1 (42+/-2 versus 59+/-3).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 180 patients were randomized into two groups using sealed envelopes.
Summary · context
Pituitary desensitization was obtained in group 1 (90 patients) with half-dose (1.87 mg) triptorelin depot in the mid-luteal phase of their menstrual cycle, and in group 2 (90 patients) with full-dose (3.75 mg) triptorelin.
Report a problemFND-1527186803
04HumanRandomized controlled trialEfficacy outcome
In ovarian stimulation patients, half-dose triptorelin produced more mature oocytes than full-dose triptorelin.
In plain wordsIn ovarian stimulation patients, half-dose triptorelin produced more mature oocytes than full-dose triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseMature oocytes
Study
n = 180
Comparator
Full-dose triptorelin 3.75 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.87 mg depot versus 3.75 mg depotAs given in this study (human).
Measurements
Mature oocytes
10.1 oocytes
half-dose triptorelin, group 1 (SD 0.54)
Mature oocytes
7.4 oocytes
full-dose triptorelin, group 2 (SD 0.55)
Source sentences
Summary
The numbers of mature oocytes (10.1+/-0.54 versus 7.4+/-0.55), of fertilized oocytes (8.24+/-0.35 versus 6.34+/-0.37) and of embryos (7.8+/-0.36 versus 5.9+/-0.37) were significantly higher in group 1.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 180 patients were randomized into two groups using sealed envelopes.
Summary · context
Pituitary desensitization was obtained in group 1 (90 patients) with half-dose (1.87 mg) triptorelin depot in the mid-luteal phase of their menstrual cycle, and in group 2 (90 patients) with full-dose (3.75 mg) triptorelin.
Report a problemFND-1527186804
05HumanRandomized controlled trialEfficacy outcome
In ovarian stimulation patients, half-dose triptorelin produced more fertilized oocytes than full-dose triptorelin.
In plain wordsIn ovarian stimulation patients, half-dose triptorelin produced more fertilized oocytes than full-dose triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseFertilized oocytes
Study
n = 180
Comparator
Full-dose triptorelin 3.75 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.87 mg depot versus 3.75 mg depotAs given in this study (human).
Measurements
Fertilized oocytes
8.24 oocytes
half-dose triptorelin, group 1 (SD 0.35)
Fertilized oocytes
6.34 oocytes
full-dose triptorelin, group 2 (SD 0.37)
Source sentences
Summary
The numbers of mature oocytes (10.1+/-0.54 versus 7.4+/-0.55), of fertilized oocytes (8.24+/-0.35 versus 6.34+/-0.37) and of embryos (7.8+/-0.36 versus 5.9+/-0.37) were significantly higher in group 1.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 180 patients were randomized into two groups using sealed envelopes.
Summary · context
Pituitary desensitization was obtained in group 1 (90 patients) with half-dose (1.87 mg) triptorelin depot in the mid-luteal phase of their menstrual cycle, and in group 2 (90 patients) with full-dose (3.75 mg) triptorelin.
Report a problemFND-1527186805
06HumanRandomized controlled trialEfficacy outcome
In ovarian stimulation patients, half-dose triptorelin produced more embryos than full-dose triptorelin.
In plain wordsIn ovarian stimulation patients, half-dose triptorelin produced more embryos than full-dose triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseEmbryos
Study
n = 180
Comparator
Full-dose triptorelin 3.75 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.87 mg depot versus 3.75 mg depotAs given in this study (human).
Measurements
Embryos
7.8 embryos
half-dose triptorelin, group 1 (SD 0.36)
Embryos
5.9 embryos
full-dose triptorelin, group 2 (SD 0.37)
Source sentences
Summary
The numbers of mature oocytes (10.1+/-0.54 versus 7.4+/-0.55), of fertilized oocytes (8.24+/-0.35 versus 6.34+/-0.37) and of embryos (7.8+/-0.36 versus 5.9+/-0.37) were significantly higher in group 1.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 180 patients were randomized into two groups using sealed envelopes.
Summary · context
Pituitary desensitization was obtained in group 1 (90 patients) with half-dose (1.87 mg) triptorelin depot in the mid-luteal phase of their menstrual cycle, and in group 2 (90 patients) with full-dose (3.75 mg) triptorelin.
Report a problemFND-1527186806
07HumanRandomized controlled trialEfficacy outcome
In ovarian stimulation patients, pregnancy rates did not differ significantly between half-dose and full-dose triptorelin.
In plain wordsIn ovarian stimulation patients, pregnancy rates did not differ significantly between half-dose and full-dose triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changePregnancy rate
Study
n = 180
Comparator
Full-dose triptorelin 3.75 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.87 mg depot versus 3.75 mg depotAs given in this study (human).
Measurements
Pregnancy rate
38.8%
half-dose triptorelin, group 1
Pregnancy rate
25.3%
full-dose triptorelin, group 2
Source sentences
Summary
No significant differences were found in pregnancy (38.8 versus 25.3%), implantation (22.6 versus 13.8%) or abortion (6.1 versus 5.0%) rates.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 180 patients were randomized into two groups using sealed envelopes.
Summary · context
Pituitary desensitization was obtained in group 1 (90 patients) with half-dose (1.87 mg) triptorelin depot in the mid-luteal phase of their menstrual cycle, and in group 2 (90 patients) with full-dose (3.75 mg) triptorelin.
Report a problemFND-1527186807
08HumanRandomized controlled trialEfficacy outcome
In ovarian stimulation patients, implantation rates did not differ significantly between half-dose and full-dose triptorelin.
In plain wordsIn ovarian stimulation patients, implantation rates did not differ significantly between half-dose and full-dose triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeImplantation rate
Study
n = 180
Comparator
Full-dose triptorelin 3.75 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.87 mg depot versus 3.75 mg depotAs given in this study (human).
Measurements
Implantation rate
22.6%
half-dose triptorelin, group 1
Implantation rate
13.8%
full-dose triptorelin, group 2
Source sentences
Summary
No significant differences were found in pregnancy (38.8 versus 25.3%), implantation (22.6 versus 13.8%) or abortion (6.1 versus 5.0%) rates.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 180 patients were randomized into two groups using sealed envelopes.
Summary · context
Pituitary desensitization was obtained in group 1 (90 patients) with half-dose (1.87 mg) triptorelin depot in the mid-luteal phase of their menstrual cycle, and in group 2 (90 patients) with full-dose (3.75 mg) triptorelin.
Report a problemFND-1527186808
09HumanRandomized controlled trialSafety outcome
In ovarian stimulation patients, abortion rates did not differ significantly between half-dose and full-dose triptorelin.
In plain wordsIn ovarian stimulation patients, abortion rates did not differ significantly between half-dose and full-dose triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeAbortion rate
Study
n = 180
Comparator
Full-dose triptorelin 3.75 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.87 mg depot versus 3.75 mg depotAs given in this study (human).
Measurements
Abortion rate
6.1%
half-dose triptorelin, group 1
Abortion rate
5%
full-dose triptorelin, group 2
Source sentences
Summary
No significant differences were found in pregnancy (38.8 versus 25.3%), implantation (22.6 versus 13.8%) or abortion (6.1 versus 5.0%) rates.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 180 patients were randomized into two groups using sealed envelopes.
Summary · context
Pituitary desensitization was obtained in group 1 (90 patients) with half-dose (1.87 mg) triptorelin depot in the mid-luteal phase of their menstrual cycle, and in group 2 (90 patients) with full-dose (3.75 mg) triptorelin.
Report a problemFND-1527186809
10HumanRandomized controlled trialEfficacy outcome
In ovarian stimulation patients, cumulative pregnancy rates were higher with half-dose than full-dose triptorelin.
In plain wordsIn ovarian stimulation patients, cumulative pregnancy rates were higher with half-dose than full-dose triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseCumulative pregnancy rate
Study
n = 180
Comparator
Full-dose triptorelin 3.75 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
1.87 mg depot versus 3.75 mg depotAs given in this study (human).
Measurements
Cumulative pregnancy rate
56.8%
half-dose triptorelin, group 1
Cumulative pregnancy rate
35.4%
full-dose triptorelin, group 2
Source sentences
Summary
Cumulative pregnancy (fresh plus frozen embryo transfers: 56.8 versus 35.4%) rate was significantly higher in group 1.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 180 patients were randomized into two groups using sealed envelopes.
Summary · context
Pituitary desensitization was obtained in group 1 (90 patients) with half-dose (1.87 mg) triptorelin depot in the mid-luteal phase of their menstrual cycle, and in group 2 (90 patients) with full-dose (3.75 mg) triptorelin.
Report a problemFND-1527186810

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.